Molecularly targeted therapies and immune checkpoint inhibitors have markedly improved the therapeutic management of advanced lung cancer. However, it still remains the leading cause of cancer-related mortality worldwide, with disease stage at diagnosis representing the main prognostic factor. Detection of ...

Liquid biopsy is a non-invasive substitute to surgical biopsies for the detection of molecular biomarkers. Liquid biopsy forms an integral part of precision...

Integrated Diagnostics today announced the e-publication of full results of a large prospective clinical trial validating its Xpresys Lung 2® in the peer-reviewed medical journal CHEST, the official journal of the American College of Chest Physicians, titled: Assessment of Plasma Proteomics ...

The therapeutic landscape of lung cancer has expanded significantly over the past decade. Advancements in molecularly targeted therapies, strategies to discover and treat resistance mutations, and development of personalized cancer treatments in the context of tumor heterogeneity and dynamic tumor ...

InVision™ ctDNA liquid biopsy platform to be used to inform therapy following surgery of curative intent Addario Lung Cancer Medical Research Institute (ALCMI), a patient-founded not-for-profit global research consortium, and Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid ...

A research group led by Prof. CHEN Xiaoping from the Guangzhou Institutes of Biomedicine and Health (GIBH) of Chinese Academy of Sciences revealed a new mechanism about exosomes from Plasmodium-infected hosts inhibit tumor angiogenesis. The study was published in Oncogenesis. Malaria infection has been ...

Owing to the role of exosome as a cargo for intercellular communication, especially in cancer metastasis, the evidence has been consistently accumulated that exosomes can be used as a non-invasive indicator of cancer. Consequently, several studies applying exosome have been ...

Exosomes derived from lung cancer cells confer cisplatin (DDP) resistance to other cancer cells. However, the underlying mechanism is still unknown. A549 resistance to DDP (A549/DDP) was established. Microarray was used to analyze microRNA (miRNA) expression profiles of A549 cells, ...

The Addario Lung Cancer Medical Institute (ALCMI), a non-profit, patient-centric, international research organization, and Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announce a clinical collaboration ...

From using fluid in the lungs to better understand the potential of immunotherapy treatments in lung cancer, to tracking circulating tumor cells in prostate cancer, to conducting RNA sequencing of cancer cell clusters from the blood of pancreatic cancer patients, ...